Table 2.
Pooled HRs, heterogeneity and publication bias for OS, DFS, PFS, RFS, and EFS in cancer patients with abnormal expression level of S6K1, p-S6K1, and p-S6.
| Factor | No. of studies | Model | Pooled HR (95%CI) | P | Heterogeneity | Publication bias | ||
|---|---|---|---|---|---|---|---|---|
| I2 | P | P of Begg's test | P of Egger's test | |||||
| S6K1 | ||||||||
| OS | 6 | F | 1.69 (1.31, 2.19) | < 0.001* | 20.9% | 0.276 | 0.133 | 0.135 |
| OS from M | 3 | R | 1.99 (0.82, 4.85) | 0.128 | 77.8% | 0.011 | – | – |
| EFS | 4 | F | 2.07 (1.49, 2.89) | < 0.001* | 0.00% | 0.484 | – | – |
| p-S6K1 | ||||||||
| OS | 18 | R | 1.71 (1.37, 2.12) | < 0.001* | 83.8% | < 0.001 | 0.596 | < 0.001 |
| OS from M | 12 | R | 1.95 (1.36, 2.80) | < 0.001* | 86.8% | < 0.001 | – | – |
| OS for ESCC | 2 | F | 2.12 (1.48, 3.02) | < 0.001* | 0.0% | 0.732 | – | – |
| OS for NSCLC | 3 | R | 4.52 (1.52, 13.45) | 0.007* | 88.3% | < 0.001 | – | – |
| OS for NPC | 2 | F | 1.53 (1.10, 2.14) | 0.012* | 0.0% | 0.725 | – | – |
| OS for BC | 3 | R | 1.08 (0.65, 1.80) | 0.766 | 72.1% | 0.028 | – | – |
| DFS | 3 | R | 1.67 (1.00, 2.77) | 0.049* | 70.5% | 0.034 | – | – |
| PFS | 4 | R | 1.47 (0.60, 3.63) | 0.402 | 84.8% | 0.001 | – | – |
| RFS | 4 | R | 0.72 (0.31, 1.69) | 0.454 | 86.0% | < 0.001 | – | – |
| p-S6 | ||||||||
| OS | 11 | F | 2.02 (1.78, 2.30) | < 0.001* | 17.7% | 0.275 | 0.592 | 0.340 |
| OS from M | 5 | F | 1.78 (1.49, 2.11) | < 0.001* | 23.0% | 0.268 | – | – |
| DFS | 3 | R | 1.54 (0.70, 3.41) | 0.287 | 76.5% | 0.014 | – | – |
| PFS | 3 | F | 2.09 (1.10, 3.98) | 0.024* | 0.0% | 0.743 | – | – |
| RFS | 4 | F | 2.21 (1.52, 3.23) | < 0.001* | 46.9% | 0.130 | – | – |
M, multivariate analysis; R, random-model; F, fixed-model.
*
p < 0.05.